Tracey Regan


Blackwell Explores Emerging Trends in Treating HER2 Metastatic Breast Cancer

March 7th 2014

Since its approval in 1998 to treat metastatic breast cancer, the anti-HER2 monoclonal antibody trastuzumab has dramatically expanded life expectancy and improved quality of life for women diagnosed with HER2-positive disease.

PCPT Trial Helps Confirm Role of 5α-Reductase Inhibitors in Prostate Cancer Prevention

December 17th 2013

Two years after the FDA denied a request to expand the indication of finasteride and other 5α-reductase inhibitors to prevent prostate cancer, a major study has cast doubt on the concerns that prompted the denial: that the drug raised the risk of more lethal cancers.

Accountable Care Organizations Come to Oncology

October 17th 2012

Integrative model unites physicians, hospitals, and payers to deliver evidence-based care and control cancer costs.

Predicting Prostate Outcomes: Nomograms Help Patients Sort Options, But Caution Is Urged

February 29th 2012

With more than 240,000 new cases expected in the United States in 2012, prostate cancer is among the nation's most common tumor types.

Value-Based Coverage Decisions: CMS Scrutinizes Provenge

August 25th 2011

In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.

Recognizing a Need for Psychiatrists in Cancer Hospitals

August 11th 2011

Dr Jimmie C. Holland was long convinced that psychological status was a critical factor not just in cancer management, but in illness more broadly.

State of Mind? Assessing the Psychosocial Needs of Patients With Cancer

August 8th 2011

Oncologists too often fail to detect the severe distress that can accompany a diagnosis and subsequent treatment.

One-Stop Fixed Pricing for Cancer Care: A Model of Transparency and Certainty

June 10th 2011

The Cancer Treatment Centers of America program will first be made available to patients with breast, colorectal, lung, and prostate cancers

A Leap in Lung Cancer Care: Early-Screening Success Prompts Push for Change

March 16th 2011

The National Lung Screening Trial (NLST), a randomized, national trial involving 53,000 current and former heavy smokers, compared the effects of 2 screening procedures for lung cancer